{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:44:30Z","timestamp":1782143070198,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000061","name":"U.S. Department of Health & Human Services | NIH | Fogarty International Center","doi-asserted-by":"publisher","award":["K01 TW010496"],"award-info":[{"award-number":["K01 TW010496"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI168238"],"award-info":[{"award-number":["R01 AI168238"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61 AI176583-01"],"award-info":[{"award-number":["R61 AI176583-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1S10OD030363-01A1"],"award-info":[{"award-number":["1S10OD030363-01A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011858","name":"African Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00986-x","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:02:37Z","timestamp":1729749757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-4726","authenticated-orcid":false,"given":"Laty G.","family":"Thiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubacar","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-660X","authenticated-orcid":false,"given":"Yicheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariama N.","family":"Pouye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Pipini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seynabou D.","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-3175","authenticated-orcid":false,"given":"Saurabh D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alassane","family":"Thiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bacary D.","family":"Sadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alassane","family":"Mbengue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Vigan-Womas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-8819","authenticated-orcid":false,"given":"Lawrence","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-1357","authenticated-orcid":false,"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-760X","authenticated-orcid":false,"given":"Amy K.","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"986_CR1","unstructured":"Organization, W. H. World malaria report 2023. (2023)."},{"key":"986_CR2","unstructured":"WHO, U. and. Reversing the Incidence of Malaria 2000\u20132015. WHO Glob. Malar. Program (2015)."},{"key":"986_CR3","doi-asserted-by":"publisher","unstructured":"Cibulskis, R. E. et al. Malaria: Global progress 2000 - 2015 and future challenges. Infectious Diseases of Poverty https:\/\/doi.org\/10.1186\/s40249-016-0151-8 (2016).","DOI":"10.1186\/s40249-016-0151-8"},{"key":"986_CR4","doi-asserted-by":"publisher","unstructured":"Balikagala, B. et al. Evidence of Artemisinin-Resistant Malaria in Africa. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2101746 (2021).","DOI":"10.1056\/nejmoa2101746"},{"key":"986_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines 5, 1\u20139 (2020).","journal-title":"npj Vaccines"},{"key":"986_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"SCTP Rts","year":"2015","unstructured":"Rts, S. C. T. P. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"986_CR7","doi-asserted-by":"publisher","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 533\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(23)02511-4 (2024)","DOI":"10.1016\/S0140-6736(23)02511-4"},{"key":"986_CR8","doi-asserted-by":"crossref","unstructured":"Thera, M. A. et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: Results of a phase 1 randomized controlled trial. PLoS One 5, (2010).","DOI":"10.1371\/journal.pone.0009041"},{"key":"986_CR9","unstructured":"Thera, M. A. et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial. PLoS One 3, (2008)."},{"key":"986_CR10","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.vaccine.2007.03.012","volume":"25","author":"ME Polhemus","year":"2007","unstructured":"Polhemus, M. E. et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research. Vaccine 25, 4203\u20134212 (2007).","journal-title":"Vaccine"},{"key":"986_CR11","doi-asserted-by":"publisher","unstructured":"Payne, R. O. et al. Demonstration of the blood-stage plasmodium falciparum controlled human malaria infection model to assess efficacy of the p. falciparum apical membrane antigen 1 Vaccine, FMP2.1\/AS01. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiw039 (2016).","DOI":"10.1093\/infdis\/jiw039"},{"key":"986_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","volume":"365","author":"MA Thera","year":"2011","unstructured":"Thera, M. A. et al. A Field Trial to Assess a Blood-Stage Malaria Vaccine. N. Engl. J. Med. 365, 1004\u20131013 (2011).","journal-title":"N. Engl. J. Med."},{"key":"986_CR13","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"986_CR14","doi-asserted-by":"crossref","unstructured":"Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, (2011).","DOI":"10.1038\/ncomms1615"},{"key":"986_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijpara.2008.10.006","volume":"39","author":"J Baum","year":"2009","unstructured":"Baum, J. et al. Reticulocyte-binding protein homologue 5 - An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 39, 371\u2013380 (2009).","journal-title":"Int. J. Parasitol."},{"key":"986_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/dde6c172-c9c3-43bb-8fc3-db54613d4424","volume":"3","author":"M Rodriguez","year":"2008","unstructured":"Rodriguez, M., Lustigman, S., Montero, E., Oksov, Y. & Lobo, C. A. PfRH5: A novel reticulocyte-binding family homolog of Plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS One 3, 1\u20138 (2008).","journal-title":"PLoS One"},{"key":"986_CR17","doi-asserted-by":"publisher","unstructured":"Payne, R. O. et al. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI insight https:\/\/doi.org\/10.1172\/jci.insight.93683 (2017)","DOI":"10.1172\/jci.insight.93683"},{"key":"986_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","volume":"4","author":"SE Silk","year":"2023","unstructured":"Silk, S. E. et al. Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med 4, 668\u2013686.e7 (2023).","journal-title":"Med"},{"key":"986_CR19","doi-asserted-by":"publisher","first-page":"e1002991","DOI":"10.1371\/journal.ppat.1002991","volume":"8","author":"AR Williams","year":"2012","unstructured":"Williams, A. R. et al. Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens. PLoS Pathog. 8, e1002991 (2012).","journal-title":"PLoS Pathog."},{"key":"986_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.vaccine.2012.10.106","volume":"31","author":"LY Bustamante","year":"2013","unstructured":"Bustamante, L. Y. et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 31, 373\u2013379 (2013).","journal-title":"Vaccine"},{"key":"986_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1073\/pnas.1415466112","volume":"112","author":"KS Reddy","year":"2015","unstructured":"Reddy, K. S. et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc. Natl Acad. Sci. Usa. 112, 1179\u20131184 (2015).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"986_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09894-4","volume":"10","author":"AD Douglas","year":"2019","unstructured":"Douglas, A. D. et al. A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates. Nat. Commun. 10, 1\u20138 (2019).","journal-title":"Nat. Commun."},{"key":"986_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","volume":"17","author":"AD Douglas","year":"2015","unstructured":"Douglas, A. D. et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe 17, 130\u2013139 (2015).","journal-title":"Cell Host Microbe"},{"key":"986_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","volume":"2","author":"AM Minassian","year":"2021","unstructured":"Minassian, A. M. et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med 2, 701\u2013719.e19 (2021).","journal-title":"Med"},{"key":"986_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","volume":"178","author":"DGW Alanine","year":"2019","unstructured":"Alanine, D. G. W. et al. Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. Cell 178, 216\u2013228.e21 (2019).","journal-title":"Cell"},{"key":"986_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4049\/jimmunol.1302045","volume":"192","author":"AD Douglas","year":"2014","unstructured":"Douglas, A. D. et al. Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5. J. Immunol. 192, 245\u2013258 (2014).","journal-title":"J. Immunol."},{"key":"986_CR27","doi-asserted-by":"publisher","unstructured":"Bei, A. K. et al. Research Article A flow cytometry-based assay for measuring invasion of red blood cells by Plasmodium falciparum. 234\u2013237 https:\/\/doi.org\/10.1002\/ajh.21642 (2010).","DOI":"10.1002\/ajh.21642"},{"key":"986_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature13715","volume":"515","author":"KE Wright","year":"2014","unstructured":"Wright, K. E. et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515, 427\u2013430 (2014).","journal-title":"Nature"},{"key":"986_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-023-04591-6","volume":"22","author":"K Miura","year":"2023","unstructured":"Miura, K. et al. Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies. Malar. J. 22, 1\u201314 (2023).","journal-title":"Malar. J."},{"key":"986_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67877-8","volume":"10","author":"Y Azasi","year":"2020","unstructured":"Azasi, Y. et al. Bliss\u2019 and Loewe\u2019s additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations. Sci. Rep. 10, 1\u201312 (2020).","journal-title":"Sci. Rep."},{"key":"986_CR31","doi-asserted-by":"crossref","unstructured":"Barrett, J. R. et al. Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype. bioRxiv 2023.10.04.560576 (2023).","DOI":"10.1101\/2023.10.04.560576"},{"key":"986_CR32","doi-asserted-by":"publisher","unstructured":"Wong, W. et al. Structure of Plasmodium falciparum Rh5\u2013CyRPA\u2013Ripr invasion complex. Nature https:\/\/doi.org\/10.1038\/s41586-018-0779-6 (2019).","DOI":"10.1038\/s41586-018-0779-6"},{"key":"986_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1003943","volume":"10","author":"GJ Wright","year":"2014","unstructured":"Wright, G. J. & Rayner, J. C. Plasmodium falciparum Erythrocyte Invasion: Combining Function with Immune Evasion. PLoS Pathog. 10, 1\u20137 (2014).","journal-title":"PLoS Pathog."},{"key":"986_CR34","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.xcrm.2021.100207","volume":"2","author":"CM Nielsen","year":"2021","unstructured":"Nielsen, C. M. et al. Protein\/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep. Med 2, 100207 (2021).","journal-title":"Cell Rep. Med"},{"key":"986_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-019-3096-0","volume":"19","author":"O Ajibaye","year":"2020","unstructured":"Ajibaye, O. et al. Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria. Malar. J. 19, 1\u201312 (2020).","journal-title":"Malar. J."},{"key":"986_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-23929-9","volume":"12","author":"K Mangou","year":"2022","unstructured":"Mangou, K. et al. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Sci. Rep. 12, 1\u201310 (2022).","journal-title":"Sci. Rep."},{"key":"986_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81711-9","volume":"11","author":"AJ Moore","year":"2021","unstructured":"Moore, A. J. et al. Assessing the functional impact of PfRh5 genetic diversity on ex vivo erythrocyte invasion inhibition. Sci. Rep. 11, 1\u20138 (2021).","journal-title":"Sci. Rep."},{"key":"986_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-021-03815-x","volume":"20","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga, L. et al. The Plasmodium falciparum Rh5 invasion protein complex reveals an excess of rare variant mutations. Malar. J. 20, 1\u201310 (2021).","journal-title":"Malar. J."},{"key":"986_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fitd.2023.1102265","volume":"4","author":"H Waweru","year":"2023","unstructured":"Waweru, H. et al. Limited genetic variations of the Rh5-CyRPA-Ripr invasion complex in Plasmodium falciparum parasite population in selected malaria-endemic regions, Kenya. Front. Trop. Dis. 4, 1\u20139 (2023).","journal-title":"Front. Trop. Dis."},{"key":"986_CR40","doi-asserted-by":"publisher","unstructured":"Silk, S. E. et al. Blood-stage malaria vaccine candidate RH5.1\/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00312-8 (2024).","DOI":"10.1016\/S1473-3099(24)00312-8"},{"key":"986_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41576-021-00349-5","volume":"22","author":"DE Neafsey","year":"2021","unstructured":"Neafsey, D. E., Taylor, A. R. & MacInnis, B. L. Advances and opportunities in malaria population genomics. Nat. Rev. Genet. 22, 502\u2013517 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"986_CR42","doi-asserted-by":"publisher","unstructured":"Manske, M. et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature https:\/\/doi.org\/10.1038\/nature11174 (2012).","DOI":"10.1038\/nature11174"},{"key":"986_CR43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1093\/infdis\/jit385","volume":"208","author":"SD Patel","year":"2013","unstructured":"Patel, S. D. et al. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J. Infect. Dis. 208, 1679\u20131687 (2013).","journal-title":"J. Infect. Dis."},{"key":"986_CR44","doi-asserted-by":"publisher","unstructured":"Triglia, T. et al. Plasmepsin X activates the PCRCR complex of Plasmodium falciparum by processing PfRh5 for erythrocyte invasion. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-023-37890-2 (2023).","DOI":"10.1038\/s41467-023-37890-2"},{"key":"986_CR45","doi-asserted-by":"crossref","unstructured":"King, L. D. W. et al. Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies (2024).","DOI":"10.1101\/2024.01.04.574181"},{"key":"986_CR46","doi-asserted-by":"publisher","unstructured":"Farrell, B. et al. Structure of the PfRCR complex which bridges the malaria parasite and erythrocyte during invasion. bioRxiv (Springer US, https:\/\/doi.org\/10.1038\/s41586-023-06856-1 2023).","DOI":"10.1038\/s41586-023-06856-1"},{"key":"986_CR47","doi-asserted-by":"publisher","unstructured":"Thiam, L. G., Ansah, F., Niang, M., Awandare, G. A. & Aniweh, Y. Short-term cryopreservation and thawing have minimal effects on Plasmodium falciparum ex vivo invasion profile. Front. Cell. Infect. Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2022.997418 (2022).","DOI":"10.3389\/fcimb.2022.997418"},{"key":"986_CR48","unstructured":"Thiam, L. G. Investigating Factors Influencing Variation in P. Falciparum Invasion Phenotyping Assays. (University if Ghana, Legon, 2019)."},{"key":"986_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-86438-1","volume":"11","author":"LG Thiam","year":"2021","unstructured":"Thiam, L. G. et al. Blood donor variability is a modulatory factor for P. falciparum invasion phenotyping assays. Sci. Rep. 11, 1\u201314 (2021).","journal-title":"Sci. Rep."},{"key":"986_CR50","unstructured":"Schrodinger, L. The PyMOL Molecular Graphics System (2015)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00986-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00986-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00986-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:04:35Z","timestamp":1729749875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00986-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00986-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.24.24305116","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMc and SJD are inventors on patent applications relating to RH5 malaria vaccines and\/or antibodies. All other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}